AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1283656 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 37
Study 1283656 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST
Number of subjects: 37
Study 1283656 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine release test
Number of subjects: 37
Study 1283656 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with fresh codfish
Number of subjects: 37
Study 4019261 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 72
Study 4019261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 31200819 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (first line)
Number of subjects: 111
Study 29733329 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX-containing dressing
Number of subjects: 57
Study 29733329 — intervention group
Group type: COMPARATOR
Intervention: Control dressing
Number of subjects: 57
Study 27543984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded cytology review
Number of subjects: 428
Study 27543984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded cytology review in HPV-negative women
Number of subjects: 428
Study 27543984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded cytology review in HPV 16+/HPV 18+ women
Number of subjects: 428
Study 27543984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded cytology review with cotesting
Number of subjects: 428
Study 27543984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded cytology review with HPV primary screening
Number of subjects: 428
Study 26448164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash reward of 150 for achieving target weight
Number of subjects: 700
Study 26448164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash reward of 300 for achieving target weight
Number of subjects: 700
Study 26448164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 700
Study 22652402 — intervention group
Group type: EXPERIMENTAL
Intervention: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given concurrently
Number of subjects: 282
Study 22652402 — intervention group
Group type: EXPERIMENTAL
Intervention: ASO3-adjuvanted H1N1pdm09 vaccine (Arepanrix, GSK) with TIV (Vaxigrip, Sanofi Pasteur) given sequentially (21 days later)
Number of subjects: 282
Study 22652402 — intervention group
Group type: COMPARATOR
Intervention: H1N1pdm09 vaccine alone
Number of subjects: 282
Study 20421240 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based falls prevention service
Number of subjects: 107
Study 20421240 — intervention group
Group type: COMPARATOR
Intervention: Domiciliary falls prevention service
Number of subjects: 107
Study 18586189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase injection (n = 71)
Number of subjects: 139
Study 18586189 — intervention group
Group type: COMPARATOR
Intervention: No injection (control group, n = 68)
Number of subjects: 139
Study 16260247 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Jeopardy style game
Number of subjects: 104
Study 16260247 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture
Number of subjects: 104
Study 11906779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccination (DTPw-HB/Hib)
Number of subjects: 400
Study 11906779 — intervention group
Group type: COMPARATOR
Intervention: Separate injection vaccination (DTPw-HB and Hib)
Number of subjects: 400
Study 11906779 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 400
Study 10422951 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg for induction followed by propofol 75‐150 microg x kg(‐1) x min(‐1) for maintenance
Number of subjects: 104
Study 10422951 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 1‐2% with N2O 67% in oxygen for maintenance
Number of subjects: 104
Study 10422951 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane in combination with N2O 67% in oxygen for induction and maintenance
Number of subjects: 104
Study 7669461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 30
Study 7669461 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 30
Study 1886362 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fixation alone
Number of subjects: 79
Study 1886362 — intervention group
Group type: COMPARATOR
Intervention: Conventional symmetrical recessions of the medial recti
Number of subjects: 79
Study 1886362 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior medial tenotomies
Number of subjects: 79
Study 1886362 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch effect
Number of subjects: 79
Study 272207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and prednisone with anthracycline
Number of subjects: 137
Study 272207 — intervention group
Group type: COMPARATOR
Intervention: Vincristine and prednisone without anthracycline
Number of subjects: 137
Study 272207 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase consolidation and CNS prophylaxis with cranial irradiation and intrathecal methotrexate
Number of subjects: 137
Study 31842977 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine plus bupivacaine hydrochloride
Number of subjects: 500
Study 31842977 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride alone
Number of subjects: 500
Study 28143471 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Manual Acupuncture (MA)
Number of subjects: 39
Study 28143471 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Electroacupuncture (DE)
Number of subjects: 39
Study 28143471 — intervention group
Group type: COMPARATOR
Intervention: Periauricular Electroacupuncture (PE)
Number of subjects: 39
Study 25762651 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour nicotine deprivation
Number of subjects: 54
Study 25762651 — intervention group
Group type: COMPARATOR
Intervention: smoked as usual
Number of subjects: 54
Study 23356491 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 44
Study 23356491 — intervention group
Group type: EXPERIMENTAL
Intervention: SV (Stanford V; doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone)
Number of subjects: 44
Study 23356491 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 44
Study 17502874 — intervention group
Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324
Study 17502874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish (3 x 150 g portions of cod/week)
Number of subjects: 324
Study 17502874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (3 x 150 g portions of salmon/week)
Number of subjects: 324
Study 17502874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (DHA/EPA capsules, no seafood)
Number of subjects: 324
Study 15539546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-model analyses of covariance
Number of subjects: 0
Study 15539546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlations (ICCs) estimates
Number of subjects: 0
Study 15539546 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulae for adjustments for fixed and time-varying covariates
Number of subjects: 0
Study 11198784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibernat (dietary fiber preparation)
Number of subjects: 114
Study 11198784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 9107166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingual nitroglycerin administration
Number of subjects: 96
Study 9107166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 8473716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg/day
Number of subjects: 12
Study 8473716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 400 mg/day
Number of subjects: 12
Study 8473716 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day
Number of subjects: 12
Study 8473716 — intervention group
Group type: EXPERIMENTAL
Intervention: All active compounds (Nefazodone and Imipramine)
Number of subjects: 12
Study 8473716 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day with alcohol
Number of subjects: 12
Study 8473716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg/day with alcohol
Number of subjects: 12
Study 2951158 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg thrice daily
Number of subjects: 17
Study 30882553 — intervention group
Group type: EXPERIMENTAL
Intervention: DrinkWise (e‐SBI)
Number of subjects: 185
Study 28938434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 0
Study 28938434 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin clamp studies
Number of subjects: 0
Study 28938434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat dietary intervention
Number of subjects: 0
Study 28938434 — intervention group
Group type: COMPARATOR
Intervention: T2D condition
Number of subjects: 0
Study 26808782 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait observation (viewing videos of healthy and parkinsonian gait)
Number of subjects: 23
Study 26808782 — intervention group
Group type: COMPARATOR
Intervention: Landscape observation (viewing videos of moving water)
Number of subjects: 23
Study 25516025 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB)
Number of subjects: 129
Study 25516025 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 129
Study 22455544 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care (IC) plus usual care (UC)
Number of subjects: 20
Study 18948027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4)
Number of subjects: 0
Study 18948027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 260/0.45 (HES 260/0.45)
Number of subjects: 0
Study 18948027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (HES 130/0.4)
Number of subjects: 0
Study 18948027 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 0
Study 17321924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg given intravenously over 10 minutes, 0.4 microg.kg‐1.h‐1, n=20)
Number of subjects: 40
Study 17321924 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.5 microg.kg‐1 bolus, 1 microg.kg‐1.h‐1, n=20)
Number of subjects: 40
Study 15343554 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of the quadriceps femoris
Number of subjects: 38
Study 15343554 — intervention group
Group type: COMPARATOR
Intervention: Arthritis education-only group
Number of subjects: 38
Study 12243105 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week basic training
Number of subjects: 76
Study 12243105 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week basic plus booster training
Number of subjects: 76
Study 12243105 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up with funding and training organizations
Number of subjects: 76
Study 9690592 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-through-needle technique (SST)
Number of subjects: 120
Study 9690592 — intervention group
Group type: COMPARATOR
Intervention: Double-segment technique (DST)
Number of subjects: 120
Study 8600747 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ankle training brace
Number of subjects: 12
Study 8600747 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallassy ankle training brace
Number of subjects: 12
Study 8600747 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Stirrup ankle training brace
Number of subjects: 12
Study 8600747 — intervention group
Group type: COMPARATOR
Intervention: No brace (control)
Number of subjects: 12
Study 2504072 — intervention group
Group type: EXPERIMENTAL
Intervention: Psomaglobin (Pseudomonas hyperimmune globulin)
Number of subjects: 25
Study 2504072 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 31911348 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of the opioid receptor antagonist naltrexone
Number of subjects: 159
Study 31911348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 31911348 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 159
Study 29779182 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator prosthesis
Number of subjects: 12
Study 29779182 — intervention group
Group type: COMPARATOR
Intervention: Ceramic/electroplated double-crown prosthesis
Number of subjects: 12
Study 27826127 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 80μg/d
Number of subjects: 0
Study 27826127 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20μg/d
Number of subjects: 0
Study 27826127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26115878 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi plus exercise training
Number of subjects: 0
Study 26115878 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic plus exercise training
Number of subjects: 0
Study 26115878 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1 receptor antagonist plus exercise training
Number of subjects: 0
Study 23332727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 7200
Study 21744082 — intervention group
Group type: EXPERIMENTAL
Intervention: L-BLP25 plus best supportive care (BSC)
Number of subjects: 171
Study 21744082 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 171
Study 21744082 — intervention group
Group type: EXPERIMENTAL
Intervention: L-BLP25 plus BSC (stage IIIB loco-regional subgroup)
Number of subjects: 171
Study 21744082 — intervention group
Group type: COMPARATOR
Intervention: BSC alone (stage IIIB loco-regional subgroup)
Number of subjects: 171
Study 19183833 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stented internal biliary drainage (group I)
Number of subjects: 46
Study 19183833 — intervention group
Group type: COMPARATOR
Intervention: Stented external biliary drainage (group E)
Number of subjects: 46
Study 17115612 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Erbisol
Number of subjects: 0
Study 15055504 — intervention group
Group type: EXPERIMENTAL
Intervention: Floor mat
Number of subjects: 11
Study 15055504 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoles
Number of subjects: 11
Study 15055504 — intervention group
Group type: COMPARATOR
Intervention: Wood-block floor
Number of subjects: 11
Study 15055504 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoles and mat conditions
Number of subjects: 11
Study 11368808 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarmed vial
Number of subjects: 100
Study 11368808 — intervention group
Group type: COMPARATOR
Intervention: Non-alarmed vial (Control)
Number of subjects: 100
Study 9227540 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml/kg body weight of 0.5 M racemic sodium lactate
Number of subjects: 14
Study 9227540 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14
Study 8435738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor training programme (5 sessions, weekly, supervised by physiotherapists)
Number of subjects: 150
Study 8435738 — intervention group
Group type: COMPARATOR
Intervention: Surgery (dissection and removal of the deep dorsal vein of the penis and its tributaries)
Number of subjects: 150
Study 2956873 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily for 4 weeks
Number of subjects: 16
Study 2956873 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given 3 times daily for 4 weeks
Number of subjects: 16
Study 2956873 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg and 100 mg, given 3 times daily
Number of subjects: 16
Study 2956873 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 150 mg, given 3 times daily
Number of subjects: 16
Study 2956873 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg, 100 mg, or 150 mg, given 3 times daily
Number of subjects: 16
Study 30285645 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy (60 min, twice a week for 12 months)
Number of subjects: 600
Study 30285645 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 30285645 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy
Number of subjects: 600
Study 27266821 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume
Number of subjects: 467
Study 27266821 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracardial adipose tissue (PAT) volume
Number of subjects: 467
Study 27266821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean attenuation of EAT
Number of subjects: 467
Study 27266821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean attenuation of PAT
Number of subjects: 467
Study 24033362 — intervention group
Group type: EXPERIMENTAL
Intervention: BisGMA-based composite restorations
Number of subjects: 59
Study 24033362 — intervention group
Group type: EXPERIMENTAL
Intervention: UDMA-based compomer restorations
Number of subjects: 59
Study 24033362 — intervention group
Group type: EXPERIMENTAL
Intervention: BisGMA-based restorations
Number of subjects: 59
Study 24033362 — intervention group
Group type: COMPARATOR
Intervention: Control (Amalgam treatment)
Number of subjects: 59
Study 24033362 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater treatment levels
Number of subjects: 59
Study 23168823 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (2000 mg daily for 90 days)
Number of subjects: 1213
Study 23168823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1213
Study 23168823 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 1213
Study 20693804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 652
Study 20693804 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 652
Study 18289809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempo inhaler
Number of subjects: 12
Study 18289809 — intervention group
Group type: COMPARATOR
Intervention: Commercial inhaler
Number of subjects: 12
Study 15919846 — intervention group
Group type: EXPERIMENTAL
Intervention: TM-CD care (n = 329) including AUC elements plus 'stage of change' assessments, mailed workbooks, and monthly calls
Number of subjects: 665
Study 15919846 — intervention group
Group type: COMPARATOR
Intervention: Augmented usual care (AUC) (n = 336) including dietary and exercise advice, prescriptions, and dietary recalls
Number of subjects: 665
Study 12771562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol intake
Number of subjects: 620
Study 12771562 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated and polyunsaturated lipids intake
Number of subjects: 620
Study 12771562 — intervention group
Group type: COMPARATOR
Intervention: Protein and carbohydrate intake
Number of subjects: 620
Study 12771562 — intervention group
Group type: COMPARATOR
Intervention: Tobacco smoking, body mass index, and regular physical activity
Number of subjects: 620
Study 12771562 — intervention group
Group type: COMPARATOR
Intervention: Height
Number of subjects: 620
Study 12771562 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 620
Study 15016225 — intervention group
Group type: EXPERIMENTAL
Intervention: Novo 27G/13 mm (N27)
Number of subjects: 100
Study 15016225 — intervention group
Group type: EXPERIMENTAL
Intervention: B-D MicroFine IV 28G/13 mm (B28)
Number of subjects: 100
Study 15016225 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoFine 28G/12 mm (N28)
Number of subjects: 100
Study 15016225 — intervention group
Group type: EXPERIMENTAL
Intervention: B-D MicroFine+ 29G/13 mm (B29)
Number of subjects: 100
Study 15016225 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoFine 30G/8 mm (N30)
Number of subjects: 100
Study 15016225 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (no needle mounted)
Number of subjects: 100
Study 15016225 — intervention group
Group type: EXPERIMENTAL
Intervention: All needles
Number of subjects: 100
Study 8970468 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV plus didanosine (ddI)
Number of subjects: 582
Study 8970468 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV plus zalcitabine (ddC)
Number of subjects: 582
Study 8970468 — intervention group
Group type: COMPARATOR
Intervention: Randomized arm (ZDV/ddI or ZDV/ddC)
Number of subjects: 582
Study 8970468 — intervention group
Group type: EXPERIMENTAL
Intervention: Open arm (ZDV/ddI or ZDV/ddC)
Number of subjects: 582
Study 8970468 — intervention group
Group type: EXPERIMENTAL
Intervention: Open arm
Number of subjects: 582
Study 8970468 — intervention group
Group type: COMPARATOR
Intervention: Randomized arm
Number of subjects: 582
Study 1633124 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile oil
Number of subjects: 22
Study 1633124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6542835 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (4.0 mmol h‐1 kg‐1 b. wht.)
Number of subjects: 6
Study 31143996 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Jugular Vein (IJV) catheterization
Number of subjects: 1484
Study 31143996 — intervention group
Group type: COMPARATOR
Intervention: Subclavian Vein (SCV) catheterization
Number of subjects: 1484
Study 28249094 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary PCI (including stent implantation)
Number of subjects: 1234
Study 28249094 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (4 repeated 30-second balloon occlusions followed by 30 seconds of reperfusion)
Number of subjects: 1234
Study 28249094 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary PCI
Number of subjects: 1234
Study 28249094 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 1234
Study 25496674 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lignocaine (7 puffs of 10% aerosol)
Number of subjects: 99
Study 25496674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (1.5 mg/kg)
Number of subjects: 99